A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas
Status:
Completed
Trial end date:
2019-01-08
Target enrollment:
Participant gender:
Summary
The study objective is to evaluate the therapeutic activity, safety and tolerability of
axitinib in patients with advanced/metastatic soft tissue sarcoma who are unsuitable for or
have relapsed after standard chemotherapy. The therapeutic activity will be separately
assessed in angiosarcoma, synovial sarcoma, leiomyosarcomas and other sarcomas.
Phase:
Phase 2
Details
Lead Sponsor:
Sheffield Teaching Hospitals NHS Foundation Trust
Collaborators:
Cancer Research UK Pfizer University of Birmingham